NCPA - National Center for Policy Analysis

Daily Policy Digest

Health Issues

American Patients Have Much, Much Better Access to Cancer Drugs Than Others Do

Of 45 anticancer drug indications approved in the United States between January 1, 2009, and December 31, 2013, 64 percent (29) were approved by the European Medicines Agency; 76 percent (34) were approved in Canada; and 71 percent (32) were approved in Australia between January 1, 2009, and June 30, 2014. The U.S. Medicare program covered all 45 drug indications; the United Kingdom covered 72 percent (21) of those approved in Europe -- only 47 percent (21) of the drug indications covered by Medicare. Canada and France covered 33 percent (15) and 42 percent (19) of the drug indications covered by Medicare, respectively, and Australia was the most restrictive country, covering only 31 percent (14), writes NCPA Senior Fellow John R. Graham...

It's Time to Rethink How We Manage, Pay for Care for The Sickest 10%

Americans are increasingly enrolling in health plans that reimburse none of their medical bills, but are costly nonetheless. Many day-to-day medical care costs are paid entirely out-of-pocket, writes NCPA Senior Fellow Devon Herrick...

Repealing Obamacare Is Good For California Jobs

Obamacare was a cash cow for providers, who now argue it was a program for jobs and economic growth. They now say that repealing Obamacare will kill California jobs. That grabs any politician's attention, but it is not true, writes NCPA Senior Fellow John R. Graham...

Celebrity Apprentice and Medical Innovation Have Something Important in Common

A new report should help President Trump find his way out of the confusion suggested by his very mixed signals on the role of medical innovation to American prosperity and patient. The same policies which protect his investment in reality TV ensure medical innovators can invest in research and development, writes NCPA Senior Fellow John R. Graham...

Who Is Responsible for Rising Drug Costs?

Americans’ prescription drug bills are rising. Most drugs are affordable, but prices for a few drugs exceed the average mortgage payment. They can be especially costly when there are only one, two or three patented drugs in a given therapeutic class. Drug makers are free to establish whatever price they believe the market will bear and, depending on the number of competitors, they could have significant pricing power.

Congressional Brief: 12 Fundamentals of Highly Effective Healthcare

Empowering Patients, Providers and the Private Sector by lowering costs, increasing quality and expanding access.

Health Construction Picked Up in December

Health facilities construction turned around in December, growing 0.6 percent versus a decline of 0.3 percent in starts for other construction. Health facilities construction accounted for almost 6 percent of non-residential construction starts. However, the growth was all in private health facilities.

Massachusetts Governor Hiking Taxes To Rescue Failed Health Reform

Governor Charlie Baker of Massachusetts has proposed a tax of $2,000 per worker on businesses which do not offer health coverage to employees who become dependent on Medicaid. This makes him the second Republican governor of Massachusetts to buy into the notion that imposing taxes (or fines or penalties or fees) on individuals and businesses can force them to accept responsibility for government failure at getting health spending under control, writes NCPA Senior Fellow John R. Graham...

Consumer Price Index: Moderate Health Price Increases

The Consumer Price Index rose 0.3 percent in December. Medical prices rose only 0.2 percent. This is the fourth month in a row we have enjoyed medical price relief. Even prices of prescription drugs rose by only 0.2 percent. Prices of health insurance even dropped a smidgeon, writes NCPA Senior Fellow John R. Graham...

Advice to Trump: Leave Medicare Drug Prices to The Free Market

President-elect Donald Trump has bashed drug prices on numerous occasions. During his campaign, he championed the idea of having the government directly negotiate the price of Medicare drugs for Part D drug plans. Trump seemingly dropped the idea later in his campaign only to resurrect it again mid-January. Many Democrats also believe the government could secure a lower price for the drugs Medicare reimburses on seniors' behalf. However, Republicans have long opposed the idea of government meddling in private markets and codified a non-interference clause in the Medicare Modernization Act of 2003, writes NCPA Senior Fellow Devon Herrick...


2 3 4 5 6 7 8  Older »